Interview with Manuel Reiberg, Manager Company Operations, Daiichi Sankyo…
Can you give our readers a brief overview of Daiichi Sankyo in Austria as well as its market positioning and growth factors in 2012? Daiichi Sankyo Austria GmbH is the…
Address: Effingergasse 21, 1160 Vienna,Austria
Tel: +43 1 48586420
Web: http://www.daiichi-sankyo.at/
Daiichi Sankyo Austria GmbH is the Austrian affiliate of Daiichi Sankyo, a global pharmaceutical company that focuses on researching and marketing innovative medications. The company’s roots extend back to 1899 and the early days of industrialization of the pharmaceutical sector.
The company itself was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of nearly €8.6 billion in fiscal year 2011, Daiichi Sankyo is one of the world’s 20 leading pharmaceutical companies. The company does business in nearly 60 countries around the world. Daiichi Sankyo’s world headquarters are in Tokyo, Japan.
The company’s roots in Europe extend back to the 1980s, when both Daiichi and Sankyo established offices in Düsseldorf, Germany. The company currently does business in 12 European countries including Austria. With nearly 2,500 employees, Daiichi Sankyo has been one of the strongest Japanese pharmaceutical companies located in Europe.
Striving for innovation is a central task of Daiichi Sankyo. Innovation is the fundamental requirement for achieving the corporate goal of developing pharmaceutical products that are the best in their class or for establishing a new class of active ingredients. Furthermore, the commitment to fulfill or exceed the high expectations of stakeholders regarding corporate services, information and organizational processes is based on innovation as a fundamental principle.
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified unmet medical needs of doctors and patients. In its research, the company aims to develop drugs that are either “Best-in-Class” or create a new class of therapeutic solutions.
While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, Daiichi Sankyo is engaged in the development of treatments for patients with thrombotic disorders and is focused on the discovery of novel oncology and cardiovascular-metabolic therapies.egulations. Detailed information about such drugs, such as the performance of our products may be provided only to medical professionals. For this reason, we can only give you an overview of our main products.
Can you give our readers a brief overview of Daiichi Sankyo in Austria as well as its market positioning and growth factors in 2012? Daiichi Sankyo Austria GmbH is the…
Dr. Christoph Zielinski, head of the organizational unit of the Comprehensive Cancer Center of Vienna (CCC), a representative of the Austrian oncological community, provides an insight into the key activities…
Harald Isemann, chairman of the Vienna Biocenter (VBC) – one of the leading life science hubs in Europe – and Managing Director of the Institute of Molecular Pathology (IMP), a…
Dr. Andreas Windischbauer, president of the Austrian Association of Full-Line Pharmaceutical Wholesalers (PHAGO) discusses the organization’s role within the Austrian pharma industry, its current challenges, price pressures, competition, and future…
Christa Wirthumer-Hoche, head of the Austrian Medicines and Medical Devices Agency (AGES) and chair of the European Medicines Agency (EMA) management board, discusses the role of AGES within Austria, similarities…
Mogens Guldberg, general manager of Novo Nordisk Austria, the Danish global powerhouse focused on innovative diabetic treatments, provides a unique insight into the obstacles associated with launching innovative products in…
Dr. Wolfgang Andiel, president of the Austrian Association of Generic Medicines (OeGV, Österreichischer Generikaverband), which acts as a unified voice to represent generics companies in Austria, provides an in-depth analysis…
Historically, Austria was the dominant political power in Central Europe under the Habsburg dynasty which ruled until World War I. Although the 20th century has been marked by significant shake…
Can you give a brief summary of how Intercell started, how it developed and where it stands today? Intercell was created in 1997 as a spinoff from Vienna University. From…
Let’s start by introducing our readers to the Austrian affiliate of Cegedim. Can you summarize Cegedim scope of activities and operations in Austria, as well as the structure of this…
In your opinion, what have been the most important developments of the healthcare market in Austria over the last three years? To start with, even though we are a national…
You have been with Grünenthal since 2004 and as the Austria Country Manager since June 2012. What were your initial goals when you took up the position and how have…
Can you give our readers a snapshot of the scope of Takeda’s operations and the organizational structure within Austria? Takeda in Austria is a top-ten player with a turnover of…
See our Cookie Privacy Policy Here